Home Imugene Limited

Imugene Limited

    Imugene Presents New HER-Vaxx Data At ESMO World Congress On Gastrointestinal Cancer

    Imugene Presents New HER-Vaxx Data At ESMO World Congress On Gastrointestinal Cancer

    A biotechnology company listed on the Australian Stock Exchange (ASX), Imugene Limited (ASX: IMU) develops cancer immunotherapies targeting B-cell peptide vaccines. The immunotherapies developed...

    A Look at Imugene’s robust pipeline of B-Cell Vaccines for Cancer Immunotherapy

    An Australian-headquartered clinical stage immuno-oncology company, Imugene Limited (ASX: IMU) has a robust pipeline of B cell vaccines aimed at treating a variety of...
    IMU

    An Insight into Imugene’s Unique Platform Technology

    Imugene Limited (ASX: IMU) is a clinical-stage immuno-oncology company headquartered in Australia that is engaged in developing a range of immunotherapies used to treat...

    A Glimpse At Biotech Company, Imugene Limited

    A biotechnology company with operations in America and Europe, Imugene Limited (ASX: IMU) deals with the development of cancer immunotherapies targeting B-cell peptide vaccines....

    Imugene Appoints Leading Biotechnology Executive and Entrepreneur-Dr Jens Eckstein

    Imugene Limited (ASX: IMU) is a clinical stage immuno-oncology firm. The company is developing a range of new and novel immunotherapies that basically activates...
    Imugene Limited Provided Quarterly Cash Flow Report For March Quarter

    Imugene Limited Provided Quarterly Cash Flow Report For March Quarter

    Biotechnology company, Imugene Limited (ASX: IMU) is an emerging leader in cancer immuno-oncology which has made significant progress in the recent past. Today, the...
    IMU

    Imugene released research study of PD-1 mimotope cancer vaccine

    Imugene Limited (ASX: IMU) is a biotechnology company, having operations in America and Europe is working specifically in the clinical stage of immuno-oncology. Immuno-oncology...
    IMU

    Imugene Presented New Data On the KEY-Vaxx & B-Vaxx Cancer Vaccine

    Imugene Limited (ASX: IMU) is an immuno-oncology company, which is into the clinical stage. The company is engaged in the operations of developing a...

    Imugene provides Guidance for KEY-Vaxx Cancer Immunotherapy

    Imugene Limited (ASX: IMU) is an ASX listed biotechnology company based in Sydney, Australia. The company’s primary focus is on the cancer immunotherapy by...
    Imugene Reports Dosing Of First Patient In The HER-Vaxx Cancer Vaccine Phase 2 Study: Shares Rose Over 5%

    Imugene Reports Dosing Of First Patient In The HER-Vaxx Cancer Vaccine Phase 2 Study:...

    Imugene Limited (ASX: IMU) is into the operations of immuno-oncology. It is in its clinical stage and is into the development of a range...

    Recent Posts